---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-308488"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2026-07-20T13:18:31+00:00"
generated_at: "2026-07-20T13:20:05.443049+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Tempus to acquire Personalis for $16.25/share, $1.5B enterprise value

## Summary
- Consideration of $16.25 per share, 6% premium to last close, 28% premium to 30-day VWAP.
- Total enterprise value of $1.5B net of Tempus' existing ownership; 100% stock with cash option up to 50%.
- Closing expected late 2026 or early 2027; subject to Personalis shareholder and regulatory approvals.
- Personalis reports preliminary Q2 revenue of $22.4M and 10,384 clinical tests, up 33% QoQ.
- Acquisition combines Personalis' MRD technology with Tempus' AI platform; MRD market opportunity $20B.

## SEC filing metadata
- accession: 0001193125-26-308488
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2026-07-20T13:18:31+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312526308488/0001193125-26-308488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312526308488/d68794d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-308488
- JSON: https://secwatch.observer/filing/0001193125-26-308488.json
- Plain text: https://secwatch.observer/filing/0001193125-26-308488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.